Akroswiss

Akroswiss is a dynamic pharmaceutical company based in Switzerland, focused on the development and commercialization of innovative nasal applications. Akroswiss is dedicated to addressing critical clinical needs through advanced pharmaceutical solutions. The company's commitment to innovation positions it as a key player in the pharmaceutical sector. Akroswiss is located at Baarstrasse 2, Zug, 6300, CH.

Akroswiss has successfully developed and tested a unique bi-dose nasal drug delivery device featuring first-class 360° functionality. This groundbreaking technology targets two significant unmet clinical needs: efficient treatment of epileptic seizures (rescue medication use) and conscious sedation ahead of diagnostic interventions against claustrophobia and restlessness (anxiolytic use). Akroswiss's cutting-edge approach underscores its dedication to improving patient outcomes and advancing healthcare.

Currently, Akroswiss is pursuing European market authorization for its midazolam product portfolio and is diligently compiling all documentation required for EMA submission. This strategic move will enable Akroswiss to expand its reach and impact within the European pharmaceutical market. We invite the manager of Akroswiss to create a customized and exclusive company showcase and product listing on our platform to further enhance your commercial development.